晚期CKD过渡至透析患者使用泻药与血钾异常风险
本研究纳入36116名2007至2015年间过渡至终末期肾病的美国退伍军人,分析过渡前1年内泻药使用与血钾异常的关系。多因素调整后,泻药使用与高钾血症风险降低独立相关(aOR 0.79,95%CI 0.76-0.84),与低钾血症风险无关(aOR 1.01,95%CI 0.95-1.07)。
要点
- 晚期CKD患者使用泻药与高钾血症风险降低独立相关。
- 泻药使用未增加低钾血症风险。
- 结果支持便秘在血钾紊乱中的潜在作用。
核心结论
- 泻药使用与晚期CKD患者过渡至ESKD前1年内高钾血症风险降低独立相关。
研究设计与样本
- 回顾性队列研究,纳入36116名2007至2015年过渡至ESKD的美国退伍军人,且过渡前1年内至少一次血钾测量。
主要发现
- 共319219次重复血钾测量,低钾血症占4.0%,高钾血症占5.0%,时间平均血钾为4.5 mEq/L。
- 多因素调整后,泻药使用与高钾血症风险降低相关(aOR 0.79;95%CI 0.76-0.84)。
- 泻药使用与低钾血症风险无关(aOR 1.01;95%CI 0.95-1.07)。
- 结果在多项敏感性分析中稳健。
关键数值与推荐
- 低钾血症定义为血钾<3.5 mEq/L,高钾血症定义为>5.5 mEq/L,正常血钾为3.5-5.5 mEq/L。
- 分析中忽略血钾异常事件后7天内的血钾测量。
临床怎么用
- 在晚期CKD患者中,可考虑泻药对高钾血症的潜在治疗作用,但需权衡风险获益。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with advanced CKD experience increased intestinal potassium excretion. This compensatory mechanism may be enhanced by laxative use; however, little is known about the association of laxative use with risk of dyskalemia in advanced CKD. METHODS: Our study population encompassed 36,116 United States veterans transitioning to ESKD from 2007 to 2015 with greater than or equal to one plasma potassium measurement during the last 1-year period before ESKD transition. Using generalized estimating equations with adjustment for potential confounders, we examined the association of time-varying laxative use with risk of dyskalemia (i.e., hypokalemia [potassium <3.5 mEq/L] or hyperkalemia [>5.5 mEq/L]) versus normokalemia (3.5-5.5 mEq/L) over the 1-year pre-ESKD period. To avoid potential overestimation of dyskalemia risk, potassium measurements within 7 days following a dyskalemia event were disregarded in the analyses. RESULTS: Over the last 1-year pre-ESKD period, there were 319,219 repeated potassium measurements in the cohort. Of these, 12,787 (4.0%) represented hypokalemia, and 15,842 (5.0%) represented hyperkalemia; the time-averaged potassium measurement was 4.5 mEq/L. After multivariable adjustment, time-varying laxative use (compared with nonuse) was significantly associated with lower risk of hyperkalemia (adjusted odds ratio [aOR], 0.79; 95% confidence interval [95% CI], 0.76 to 0.84) but was not associated with risk of hypokalemia (aOR, 1.01; 95% CI, 0.95 to 1.07). The results were robust to several sensitivity analyses. CONCLUSIONS: Laxative use was independently associated with lower risk of hyperkalemia during the last 1-year pre-ESKD period. Our findings support a putative role of constipation in potassium disarrays and also support (with a careful consideration for the risk-benefit profiles) the therapeutic potential of laxatives in hyperkalemia management in advanced CKD.
引用
- Sumida K, Dashputre AA, Potukuchi PK, et al. Laxative Use and Risk of Dyskalemia in Patients with Advanced CKD Transitioning to Dialysis. J Am Soc Nephrol. 2021. PMID: 33547216. doi:10.1681/ASN.2020081120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。